Cardiology is undergoing a year of rapid change, driven by innovations that are expanding diagnostic capabilities, advancing treatment options and personalizing care. From artificial intelligence and regenerative medicine to next-generation devices and targeted therapies, these breakthroughs are shaping how heart disease is detected, managed and, in some cases, prevented.
- AI detects hidden structural heart disease – New York City-based Columbia University and NewYork-Presbyterian’s ‘EchoNext’ analyzes ECGs to flag structural heart issues, outperforming cardiologists (77% vs. 64%) and identifying thousands of undiagnosed cases.
- FDA expands pulsed-field ablation use – Boston Scientific’s Farapulse PFA system is now approved to treat persistent drug-resistant atrial fibrillation, offering a safer, more precise alternative to traditional ablation.
- AI streamlines PCI evaluation – A noninvasive, AI-powered angiography technique matches traditional PCI evaluation accuracy, potentially reducing the need for invasive assessment before stenting.
- Artificial heart advances in U.S. trials – BiVACOR’s magnetically levitated total artificial heart, with FDA breakthrough device designation, shows promising early results in feasibility studies as a transplant alternative.
- GLP-1 drugs deliver heart benefits – GLP-1 receptor agonists, initially approved for diabetes and weight loss, are demonstrating significant reductions in major cardiovascular events in high-risk patients, driving a surge in U.S. cardiology use and ongoing clinical trials.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.